Response to Brandt, Bednarz-Knoll, Kleinheinz et al

Affiliations

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
² Department of Oncology, Kaiser Permanente, San Francisco, CA, USA.
³ Washington University at St. Louis, St. Louis, MO, USA.
⁴ Department of Pathology, University of Chicago, IL, USA.
⁵ Division of Research, Kaiser Permanente, Oakland, CA, USA.

Comment

Anil K Chaturvedi et al. J Natl Cancer Inst. 2020.

. 2020 Sep 1;112(9):970-971.

doi: 10.1093/jnci/djaa075.

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
² Department of Oncology, Kaiser Permanente, San Francisco, CA, USA.
³ Washington University at St. Louis, St. Louis, MO, USA.
⁴ Department of Pathology, University of Chicago, IL, USA.
⁵ Division of Research, Kaiser Permanente, Oakland, CA, USA.

No abstract available

Comment on

Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.
Chaturvedi AK, Udaltsova N, Engels EA, Katzel JA, Yanik EL, Katki HA, Lingen MW, Silverberg MJ. Chaturvedi AK, et al. J Natl Cancer Inst. 2020 Oct 1;112(10):1047-1054. doi: 10.1093/jnci/djz238. J Natl Cancer Inst. 2020. PMID: 31860085 Free PMC article.
RE: Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.
Brandt BH, Bednarz-Knoll N, Kleinheinz J, Franke A, Fillies T. Brandt BH, et al. J Natl Cancer Inst. 2020 Sep 1;112(9):968-969. doi: 10.1093/jnci/djaa074. J Natl Cancer Inst. 2020. PMID: 32483602 Free PMC article. No abstract available.

1. Brandt BB-K, Kleinheinz J, Franke A, Fillies T.. Re: Oral leukoplakia and risk of progression to oral cancer: a population-based cohort study. J Natl Cancer Inst. 2020. - PMC - PubMed
1. Wentzensen N, Wacholder S.. From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov. 2013;3(2):148–157. - PMC - PubMed
1. Castle PE. Teaching moment: why promising biomarkers do not always translate into clinically useful tests. J Clin Oncol. 2014;32(4):359–361. - PubMed
1. William WN Jr, Papadimitrakopoulou V, Lee JJ, et al.Erlotinib and the risk of oral cancer: the Erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA Oncol. 2016;2(2):209–216. - PMC - PubMed
1. Mehanna HM, Rattay T, Smith J, McConkey CC.. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck. 2009;31(12):1600–1609. - PubMed